Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'

Scientist,Pipetting,At,A,Biomedical,Laboratory

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Tuesday agreed to acquire Astria Therapeutics, Inc. (NASDAQ:ATXS) for a mix of cash and stock.

The deal represents an implied value of $13 per Astria share, and approximately $700 million in enterprise value.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.